References
- Delem A, Lobmann M, Zygraich N. A bovine rotavirus developed as a candidate vaccine for use in humans. J Biol Stand 1984; 12: 443–445
- Vesikari T, Isolauri E, D'Hondt E, Delem A, André FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus vaccine. Lancet 1984; 1: 977–981
- Vesikari T, Isolauri E, Delem A, D'Hondt E, Andre FE, Beards GM, Flewett TH. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985; 107: 189–194
- De Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull WHO 1985; 63: 569–583
- Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection, a prospective longitudinal study in young children. N Engl J Med 1983; 309: 72–76
- Ruuska T, Vesikari T. Rotavirus disease in Finnish children: Use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22: 259–267
- Vesikari T, Ruuska T, Delem A, André FE. Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine a preliminary report. Pediatr Infect Dis J 1987; 6: 164–169
- Hjelt K, Grauballe PC, Paerregaard A, Nielsen OH, Krasilnikoff PA. Protective effect of pre-existing rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J. Med Virol 1987; 21: 39–47
- Flores J, Perez-Schael I, Gonzales M, Garcia D, Perez M, Daoud N, Cunto W, Chanock RM, Kapikian AZ. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987; 1: 882–884
- Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, Jobe O, Sillah H, Hayes R, M'Boge BH, Whittle HC, Greenwood BM. A trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 2: 1342–1345
- Santosham M, Letson GW, Reid R, Wolff M, Gahagam S, Stypula R, Kapikian AZ, Sack RB. A field study of the safety and efficacy of two candidate rotavirus vaccines. ICAAC, Abstract 15. 1987
- Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effects of WC3 vaccine against rotavirus diarrhoea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988; 158: 570–586
- Vesikari T, Ruuska T, Delem A, André FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine (at birth and 7 months of age) for prevention of rotavirus diarrhoea, Submitted for publication
- Vesikari T, Ruuska T, Delem A, André FE. Oral rotavirus vaccination in breast -and bottle-fed infants aged 6 to 12 months. Acta Paediatr Scand 1986; 75: 573–578
- Lanata CF, Black RE, Aquila R, Gil A, Verastegui H, Gerna G, Flores J, Kapikian AZ, André FE. Protection of Peruvian children against rotavirus diarrhoea of specific serotypes by the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159: 452–459
- Offit PA, Dudzik KI. Rotavirus-specific cytotoxic T-lymphocytes cross-react with target cells infected with different rotavirus serotypes. J Viral 1988; 62: 127–131
- Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikain A, Dolin R. The Elmwood and Panorama Pediatric Groups: Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988; 7: 645–650